These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2832869)

  • 1. Ascorbate antagonizes the behavioral effects of amphetamine by a central mechanism.
    White LK; Carpenter M; Block M; Basse-Tomusk A; Gardiner TW; Rebec GV
    Psychopharmacology (Berl); 1988; 94(2):284-7. PubMed ID: 2832869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrastriatal infusions of ascorbate antagonize the behavioral response to amphetamine.
    White LK; Maurer M; Kraft ME; Oh C; Rebec GV
    Pharmacol Biochem Behav; 1990 Jul; 36(3):485-9. PubMed ID: 2377651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
    Pierce RC; Rowlett JK; Bardo MT; Rebec GV
    Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs.
    Rebec GV; Centore JM; White LK; Alloway KD
    Science; 1985 Jan; 227(4685):438-40. PubMed ID: 4038426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated treatment with ascorbate or haloperidol, but not clozapine, elevates extracellular ascorbate in the neostriatum of freely moving rats.
    Pierce RC; Clemens AJ; Shapiro LA; Rebec GV
    Psychopharmacology (Berl); 1994 Sep; 116(1):103-9. PubMed ID: 7862921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol.
    Rebec GV; Peirson EE; McPherson FA; Brugge K
    Psychopharmacology (Berl); 1982; 77(4):360-6. PubMed ID: 6813898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine-, NMDA- and sigma-receptor antagonists exert differential effects on basal and amphetamine-induced changes in neostriatal ascorbate and DOPAC in awake, behaving rats.
    Pierce RC; Rebec GV
    Brain Res; 1992 May; 579(1):59-66. PubMed ID: 1352478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy.
    Tschanz JT; Rebec GV
    Pharmacol Biochem Behav; 1988 Nov; 31(3):519-22. PubMed ID: 3251235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Endorphin involvement in the antidopaminergic effect of caerulein.
    Matsubara K; Matsushita A
    Jpn J Pharmacol; 1986 Mar; 40(3):417-22. PubMed ID: 2940395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic behavioral effects of calcitonin and amphetamine in the rat.
    Twery MJ; Kirkpatrick B; Lewis MH; Mailman RB; Cooper CW
    Pharmacol Biochem Behav; 1986 May; 24(5):1203-7. PubMed ID: 3725826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural profile of partial D2 dopamine receptor agonists. 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy.
    Clark D; Furmidge LJ; Petry N; Tong ZY; Ericsson M; Johnson D
    Psychopharmacology (Berl); 1991; 105(3):381-92. PubMed ID: 1686815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli.
    Bardo MT; Bowling SL; Pierce RC
    Psychopharmacology (Berl); 1990; 101(3):338-43. PubMed ID: 2163539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol, but not apomorphine, differentially affects low response rates of male and female Wistar rats.
    Van Hest A; van Haaren F; van de Poll NE
    Pharmacol Biochem Behav; 1988 Mar; 29(3):529-32. PubMed ID: 3362947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity.
    Klawans HL; D'amico DJ; Nausieda PA; Weiner WJ
    Psychopharmacology (Berl); 1977 Nov; 55(1):49-52. PubMed ID: 414261
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-amphetamine and haloperidol.
    Oades R; Taghzouti K; Simon H; Le Moal M
    Psychopharmacology (Berl); 1985; 85(1):123-8. PubMed ID: 3920694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of both D1 and D2 dopamine receptors increases behavioral activation and ascorbate release in the neostriatum of freely moving rats.
    Pierce RC; Rebec GV
    Eur J Pharmacol; 1990 Dec; 191(3):295-302. PubMed ID: 1982267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of AP-5- and amphetamine-induced behaviour by timelotem as compared with clozapine and haloperidol.
    Schmidt WJ; Krähling H; Ruhland M
    Life Sci; 1987 Oct; 41(16):1909-14. PubMed ID: 2889124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of both D1- and D2-dopamine receptors inhibits amphetamine-induced ascorbate release in the neostriatum.
    Oh C; Gardiner TW; Rebec GV
    Brain Res; 1989 Feb; 480(1-2):184-9. PubMed ID: 2565749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
    Biazzi A; Fregnan GB
    Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.